Objectives: Widespread use of fluoroquinolones has led to increased levels of resistance in clinical isolates of Escherichia coli. We investigated the evolution of ciprofloxacin susceptibility and molecular epidemiology of clinical E. coli isolates in haematology patients receiving ciprofloxacin prophylaxis on the population and individual patient level.
Introduction
Widespread use of fluoroquinolones in human and veterinary medicine has led to increased levels of fluoroquinolone resistance in clinical isolates of Escherichia coli. 1 -6 Fluoroquinolone resistance in E. coli has been associated with higher mortality rates due to inappropriate antibiotic treatment. 3, 7 The most common mechanism of fluoroquinolone resistance in E. coli is chromosomal mutation of the genes encoding the two fluoroquinolone target enzymes (DNA gyrase and topoisomerase IV). These mutations occur most commonly in the gyrA and parC genes in an area termed the quinolone resistance-determining region (QRDR). 8 Mutations in parC are only found in combination with mutations in gyrA. 9, 10 In patients receiving ciprofloxacin prophylaxis, emergence of ciprofloxacin-resistant E. coli can occur as the result of: (i) clonal spread from another patient colonized with ciprofloxacinresistant E. coli; (ii) selection of pre-existing ciprofloxacin-resistant strains under selective pressure; or (iii) de novo resistance mutation in ciprofloxacin-susceptible E. coli.
Emergence of fluoroquinolone resistance in E. coli likely occurs in the gastrointestinal tract, especially in patients receiving fluoroquinolones for selective intestinal decontamination. 11 In these patients, quinolone-resistant Enterobacteriaceae may rapidly emerge. 12 -14 Colonization usually precedes infection, and massive colonization with fluoroquinolone-resistant Enterobacteriaceae is therefore considered a risk factor for so-called breakthrough bacteraemia in cancer patients. In previous clinical and epidemiological studies on fluoroquinolone resistance, either cross-sectional or longitudinal, analyses of resistance were mostly performed at the population level, with only limited characterization of isolates within individual patients. 10,13 -17 The aim of this study was to prospectively investigate the molecular evolution of quinolone resistance genes and the genetic relatedness of E. coli strains both at the population level and the level of individual patients. For this purpose, all E. coli isolates obtained from patients admitted to a haematology/oncology department where fluoroquinolone prophylaxis during neutropenia was the standard of care were investigated.
Patients and methods

Patients
This study was part of common practice and, according to Dutch regulation, did not require permission from the local Medical Ethical Committee.
The University Medical Centre of Utrecht is a 1042 bed Dutch academic tertiary-care hospital. It includes a specialized haematology/ oncology service. The yearly number of admissions to the medical service ranges between 29 000 and 30 000, which includes 380-395 admissions of cancer patients to the haematology/oncology service, with, on average, 90 autologous or allogeneic bone marrow transplants each year.
Institutional guidelines recommended antibacterial prophylaxis with 500 mg twice daily oral ciprofloxacin when the expected duration of neutropenia was ≥7 days. Surveillance cultures were done from all patients at baseline and weekly during admission. If ciprofloxacin-resistant strains were found, ciprofloxacin prophylaxis was replaced by co-trimoxazole. In case of a clinical suspicion of infection, samples were obtained for diagnostic purposes as part of standard clinical practice.
Bacterial isolates
From August 2006 through December 2007 all E. coli isolates from surveillance and infection-site cultures were collected for analysis. E. coli isolates were identified and their susceptibilities were obtained using automatic methods (BD Phoenix Automated Microbiology System BD Diagnostics, Sparks, MD, USA) and/or the Etest method. Susceptibility to fluoroquinolones other than ciprofloxacin was not tested. The isolates were then stored at 2708C until molecular studies were performed.
Preparation of target DNA
DNA isolation was carried out on a MagNA Pure LC system (Roche Diagnostics, Rotkreuz, Switzerland) using the bacterial DNA Isolation Kit III (Roche) according to the manufacturer's instructions. Briefly, a single colony from a pure culture of E. coli was suspended in 100 mL molecular grade water (Sigma Aldrich, Poole, UK) and incubated for 10 min at 958C. A total of 43.50 mL of this suspension was mixed with 56.5 mL lysis buffer from the bacterial DNA Isolation Kit III (Roche). The resulting suspension of 100 mL was then added to the MagNA Pure LC sample cartridge. The DNA isolation was carried out using the bacterial DNA Isolation Kit III protocol. DNA was stored at 48C until analysis.
Analysis of the gyrA gene
PCR amplification
For analysis of the QRDR of the gyrA gene, a 196 bp gyrA fragment was amplified by PCR using the forward primer 5 ′ -CCGCCCGCCG CGCCCCGCGCCCGGCCCGCCGCCCCCGCCCC CGT ACT TTA CGC CAT GAA CG-3 ′ and the reverse primer 5 ′ -CGA TAG AAC CGA AGT TAC CC-3 ′ . The 41 bp GC clamp was added to the forward primer to prevent complete melting of the DNA fragment during denaturing gradient gel electrophoresis (DGGE) analysis. Amplification was performed in a GeneAmp PCR System 2700 (Applied Biosystems, Foster City, CA, USA) using the following protocol: one denaturing step at 948C for 5 min followed by 25 cycles of 948C for 0.5 min, 608C for 0.5 min and 728C for 0.5 min, then a final extension step of 728C for 7 min.
DGGE analysis
The PCR product was analysed by DGGE. The DGGE fragment spanned from amino acid 48 to 113. DGGE was performed essentially as described previously. 18 Briefly, PCR products were separated on a 1.5 mm thick vertical gel containing 8% (w/v) polyacrylamide and a linear gradient of the denaturants urea and formamide, increasing from 35% at the top of the gel to 55% at the bottom. This gel was loaded on a DGGE DCODE system (BioRad, Hercules, CA, USA) and run at 60 V for 16 h. After electrophoresis, the gel was stained in ethidium bromide for 30 min, washed in distilled water and viewed under ultraviolet (UV) light.
Sequencing DGGE types
Each DGGE band was sequenced in duplicate in a Big Dye terminator reaction (Applied Biosystems) on an ABI 377 sequencer, following the manufacturer's instructions. To amplify the DNA, the same protocol was used as for DGGE analysis except for the forward primer. The primer used lacked the GC clamp. Obtained sequences were assembled and analysed using the Staden package (http://staden.sourceforge.net/).
Epidemiological analysis
The genetic relatedness of the E. coli strains was determined by molecular typing using the single-enzyme amplified fragment length polymorphism (seAFLP) technique.
Ten microlitres of each DNA isolate were digested with HinfI (378C, 30 min). The partially complementary oligonucleotides 5 ′ -GTC TGC AGC ACG CT-3 ′ and 5 ′ -ATT AGC GTG CTG CAG ACC AG-3 ′ were used as adapters and ligated to the digested DNA using T4 DNA ligase (378C, 60 min). The ligation reaction was stopped by incubation at 658C for 20 min. The restriction fragments were then amplified by PCR using the primer 5 ′ -CTG CAG CAC GCT AAT CAG-3 ′ in an ABI GeneAmp PCR System 2700 (Applied Biosystems) using the following cycle program: an initial denaturation step at 958C for 5 min, 33 cycles of denaturation at 948C for 60 s, annealing at 608C for 60 s and extension at 728C for 150 s. All amplification products were fully extended at 728C for 7 min. Of each amplification product, 15 mL was then analysed on a 2% agarose gel (gel length 16 cm) at 200 V for 90 min. Amplification products were visualized by ethidium bromide staining. Cluster analysis was performed using Bionumerics software, version 5.1 (Applied Maths NV, Sint-Martens-Latem, Belgium), with the Pearson product moment correlation coefficient as a similarity measure and UPGMA (unweighted pair group method with arithmetic mean) for grouping. Isolates with banding patterns that were at least 95% similar were considered to be of the same type.
van Hees et al.
qnrA
The presence of the qnrA gene was determined by real-time PCR using the ABI Prism 7000 sequence detection system (Applied Biosystems). Primers to amplify the qnrA gene were 5 ′ -GCC GCT GCC GCT TTT A-3 ′ and 5 ′ -AAT CCT CGA AAC TGG CAT C-3 ′ . To detect the amplification in real time, a TaqMan probe was used: VIC-TCA GTG TGA CTT CAG C-MGB. PCR was performed in 45 cycles using the standard ABI Prism protocol. A clinical isolate (Enterobacter cloacae) with CTX-M and qnrA was used as positive control.
Statistical analysis
The chi-square test was applied to establish differences.
Results
Patients and bacteria
The mean number of isolates per patient was 2.4 (range 1 -20) and more than one isolate was obtained from 49% of patients. A total of 122 strains were ciprofloxacin resistant (30%) and 282 strains (70%) were ciprofloxacin susceptible. In 124 patients, only ciprofloxacin-susceptible strains were detected. Some patients had ciprofloxacin-resistant E. coli cultured even before the start of ciprofloxacin prophylaxis, possibly because they had ciprofloxacin prophylaxis before our study period. Thirty-six extended-spectrum b-lactamase (ESBL)-producing E. coli were recovered in 21 patients. Eighteen of these 36 strains (from 13 patients) were ciprofloxacin resistant as well.
Analysis of the gyrA and qnrA genes DNA was available for molecular analysis from 364 of 404 E. coli strains. To investigate whether additional mutations in the gyrA gene as well as those described in the literature could be detected, 364 strains were analysed by DGGE. This revealed 11 different gyrA patterns, representing 11 different gyrA alleles (Table 1) . To determine the sequence of the gyrA alleles, at least two representatives of each allele were sequenced. DNA sequencing and comparison of the sequence of the QRDR of gyrA with known DNA sequences of the E. coli gyrA gene (accession number x5174) revealed nucleotide changes at amino acid codons 83, 85, 87, 91 and 100 (Table 1) . Five different DGGE patterns (C, D, E, H and I) were combinations of the two most common gyrA mutations, Ser83Leu and Asp87Asn. In six different patterns (B, C, E, F, G and I) a consistent combination of silent mutations was observed in codons 85, 91 and 100. No other nucleotide changes were found in the region between codon 48 and 113. DGGE types A-E were found frequently, while F-K were all found once. The most common DGGE pattern in our study was the wild-type allele type B (51%), followed by type E (20%), which had both amino acid changes. Of the 364 isolates, 126 had at least one mutation in the gyrA gene, affecting their susceptibility to ciprofloxacin. DGGE types A-C and F-K were exclusively found in ciprofloxacin-susceptible isolates. None of the ciprofloxacinsusceptible strains had the Asp87Asn mutation, and except for strains with DGGE types C and H, none of the ciprofloxacinsusceptible strains had the Ser83Leu mutation. DGGE types D and E were only present in ciprofloxacin-resistant strains. All resistant strains had the Ser83Leu and Asp87Asn mutations. Table 1 shows the distribution of MICs of the different DGGE types.
qnrA PCR was performed on the first 100 strains. The qnrA gene was not detected in any of these isolates. 
Ciprofloxacin resistance in haematology patients
Clonal relatedness of ciprofloxacin-resistant and -susceptible E. coli seAFLP was performed to assess the clonal relatedness of 162 E. coli strains from 43 patients. These 43 patients were selected because they had E. coli with different DGGE types ( Table 2 ). This revealed the occurrence of two different mechanisms of ciprofloxacin-resistant E. coli acquisition in individual patients: (i) selection or acquisition of ciprofloxacin-resistant strains unrelated to the susceptible E. coli strain in the same patient; and (ii) acquisition of a de novo resistance mutation in ciprofloxacinsusceptible E. coli. In 12 of 43 patients (28%), ciprofloxacinsusceptible E. coli with gyrA types A, B or C were replaced by genetically distinct (different AFLP type) ciprofloxacin-resistant strains with gyrA type D or E. This indicates that the emergence of ciprofloxacin-resistant E. coli in these patients is the result of acquisition or selection of resistant E. coli clones rather than acquisition of de novo resistance mutations in indigenous E. coli clones. In four patients a switch in DGGE pattern that resulted in a significant decrease in ciprofloxacin susceptibility was noticed in E. coli isolates from the same patient that were indistinguishable by AFLP. For example, in one patient a ciprofloxacin-resistant E. coli with gyrA DGGE type E was isolated after 4 weeks of ciprofloxacin prophylaxis. Four months later a ciprofloxacin-susceptible E. coli with the same AFLP type was isolated carrying gyrA DGGE type B. This patient had not received any ciprofloxacin in those 4 months. In another patient, the first recovered E. coli was ciprofloxacin resistant with gyrA DGGE type E; 5 months later a ciprofloxacin-susceptible E. coli carrying gyrA DGGE type B with the same AFLP type was isolated. These two patients probably represent cases of reversion of mutated gyrA to wild type. At the same time that a ciprofloxacin-susceptible strain was isolated from patient 10, a ciprofloxacin-resistant but genetically distinct E. coli with DGGE type E was also isolated, indicating independent selection or acquisition of a second ciprofloxacinresistant clone.
To quantify the relative contribution of the clonal spread of resistant clones versus endogenous selection of pre-existing resistant clones, all ciprofloxacin-resistant strains (n ¼37) from all included patients were compared by AFLP. This revealed nine different AFLP clusters, of which five clusters contained two isolates, two clusters had three isolates and two clusters (5 and 6) had four isolates. Thirteen AFLP types were unique (Figure 1 ).
Discussion
Fluoroquinolone resistance is emerging as a major type of antibacterial resistance in E. coli, with reported resistance rates in haematological populations exceeding 50%. 16 In this study of 404 E. coli strains from 169 consecutively studied haematology patients receiving fluoroquinolone prophylaxis the prevalence of ciprofloxacin resistance was 27%. In 100 isolates tested the qnrA gene could not be detected.
In-depth molecular analysis by a combination of DGGE and DNA sequencing revealed a good correlation between the ciprofloxacin MIC values and different gyrA sequence patterns observed, indicating that the main mechanism of ciprofloxacin resistance in the E. coli strains of our patient population is the accumulation of Ser83Leu and Asp87Asn mutations in the gyrA gene. These mutations in the QRDR have been described previously by Heisig (1993) , Ouabdesselam (1995) , Oram and Fisher, and Conrad (1996) . 19 -22 In addition, we identified an Asp87Gly mutation in combination with silent mutations in codons 85, 91 and 100 in susceptible and resistant strains. Asp87Gly in combination with silent mutations has been described before, but not interpreted. 19 -23 In total, we found silent mutations in 77% of the strains, mostly in the predominant DGGE types, type B and type E. In these 367 isolates, no evidence for additional mutations in the gyrA gene was found. We identified two routes for E. coli to acquire a gyrA resistant genotype: DGGE type A H D and DGGE type B C E ( Table 1) . The prevalence ratio DGGE type A/DGGE type B (45/186) is significantly lower than the same ratio for DGGE type D and DGGE type E (32/74) (P ¼0.03, chi-square test), which may indicate a relative impediment of genotype B compared with A to evolve into its fully fluoroquinolone-resistant counterpart. The only difference in the gyrA fragment analysed between the two sets of genotypes A/H/D and B/C/E (apart from the 83 and 87 mutations) are the three consistently linked silent mutations at codons 85, 91 and 100. These mutations may somehow be related to this difference in rate of mutagenicity of the 83 and 87 codons between genotype A and B.
Molecular typing confirmed previous observations of a limited risk of nosocomial transmission of fluoroquinolone-resistant E. coli among haematology/oncology patients. 13, 15, 24, 25 However, the finding that nine AFLP types were shared among 2 -4 patients suggests that occasionally events of crosstransmission have occurred.
Twelve of 169 patients (7%) were colonized with distinct (different seAFLP types) susceptible and resistant E. coli clones, suggesting selection of pre-existing ciprofloxacin-resistant strains under prophylaxis or acquisition of resistant strains. Ciprofloxacin-susceptible and -resistant E. coli with different gyrA DGGE types but identical AFLP types were identified in 4 patients (2.3%). This demonstrates acquisition of de novo resistance mutations by indigenous susceptible E. coli under ciprofloxacin therapy.
Prophylactic use of antibiotics, like ciprofloxacin, in neutropenic patients remains controversial. In our study we observed that in 45/169 patients (27%), fluoroquinolone-resistant E. coli strains can be demonstrated either from the onset or during follow-up. Many of these strains apparently are pre-existing and are selected during prophylaxis, but we also provide evidence for in vivo mutation to a resistant phenotype of previously susceptible strains. Recent van Hees et al.
reviews and meta-analysis studies suggest that prophylactic treatment results in a reduction in death from all causes. 26 -31 However, these conclusions are based on original studies performed before 2005 and therefore do not take sufficiently into account the increased prevalence of fluoroquinolone-resistant Gram-negative strains observed in recent years, which may lead to a reduced efficacy of fluoroquinolone prophylaxis. Our study underlines the necessity for an ongoing discussion on this topic and the need for alternative strategies for patients in whom fluoroquinolone-resistant Gram-negative strains have been detected.
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